Trellus Management Company, LLC Adaptimmune Therapeutics PLC Transaction History

Trellus Management Company, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 05, 2018	SELL	$8.27 - $13.56 $136,157 - $223,251	-16,464 Closed	0 $0
Q2 2018 Jul 25, 2018	BUY	$10.42 - $13.74 $171,554 - $226,215	16,464 New	16,464 $195,000
Q1 2018 May 02, 2018	SELL	$7.1 - $11.56 $173,843 - $283,046	-24,485 Closed	0 $0
Q4 2017 Feb 02, 2018	BUY	$6.68 - $8.74 $163,559 - $213,998	24,485	24,485 $164,000

145M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $99.7M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Trellus Management Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Trellus Management Company, LLC with notifications on news.